ArticlePloS one2026
Pachymic acid alleviates circadian rhythm disorders in high-fat diet-induced obesity mice via the sphingolipid pathway.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity caused by a high-fat diet (HFD) is known to disrupt metabolic homeostasis and circadian rhythms. Pachymic acid (PA), a bioactive triterpenoid, exhibits anti-inflammatory, antihyperglycemic, antihyperlipidemic, and sedative-hypnotic properties, though its role in circadian regulation remains unexplored.
methodsWe assessed PA's impact on metabolic dysfunction (glucose/lipid profiles), systemic inflammation using biochemical assays, ELISA, Oil Red O staining. Circadian parameters were evaluated via 24-h serum melatonin and core body temperature. Hepatic circadian gene oscillations and mechanistic pathways were analyzed through time-series RNA sequencing, bioinformatics, qPCR, and Western blotting.
resultsPA intervention attenuated obesity-related phenotypes, including reduced body weight, improved glucose/lipid metabolism, and restored physiological rhythms of melatonin and body temperature. And hepatic gene oscillation patterns were realigned to circadian synchrony. Mechanistically, PA ameliorated liver inflammation by modulating the sphingolipid pathway, specifically via S1PR4/TRAF2 signaling.
conclusionsOur findings illustrate PA's role in mitigating metabolic and circadian disruptions in obesity, highlighting the sphingolipid pathway as a tissue-specific target for circadian modulation. This study provides novel insights into therapeutic strategies for obesity-associated circadian disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.